[go: up one dir, main page]

RU2018129760A - Фармацевтический препарат, содержащий полимерное производное на основе камптотецина - Google Patents

Фармацевтический препарат, содержащий полимерное производное на основе камптотецина Download PDF

Info

Publication number
RU2018129760A
RU2018129760A RU2018129760A RU2018129760A RU2018129760A RU 2018129760 A RU2018129760 A RU 2018129760A RU 2018129760 A RU2018129760 A RU 2018129760A RU 2018129760 A RU2018129760 A RU 2018129760A RU 2018129760 A RU2018129760 A RU 2018129760A
Authority
RU
Russia
Prior art keywords
group
optionally substituted
hydrogen atom
polyglutamic acid
integer
Prior art date
Application number
RU2018129760A
Other languages
English (en)
Other versions
RU2018129760A3 (ru
Inventor
Син АОКИ
Синъя ФУДЗИТА
Original Assignee
Ниппон Каяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ниппон Каяку Кабусики Кайся filed Critical Ниппон Каяку Кабусики Кайся
Publication of RU2018129760A publication Critical patent/RU2018129760A/ru
Publication of RU2018129760A3 publication Critical patent/RU2018129760A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (17)

1. Фармацевтический препарат, содержащий:
блок-сополимер полиэтиленгликолевого сегмента и сегмента полиглутаминовой кислоты, соединенных вместе, при этом указанный сегмент полиглутаминовой кислоты содержит звено глутаминовой кислоты, содержащее связанное с ним производное камптотецина; и
одну или более добавок, выбранных из группы, состоящей из аргинина, гистидина и хлорида натрия,
при этом указанный блок-сополимер представляет собой блок-сополимер, представленный общей формулой (1):
Figure 00000001
где
R1 представляет собой атом водорода или необязательно замещенную (С1-С6) алкильную группу;
А представляет собой (С1-С6) алкиленовую группу;
R2 представляет собой любую группу, выбранную из группы, состоящей из атома водорода, необязательно замещенной (С1-С6) ацильной группы и необязательно замещенной (С1-С6) алкоксикарбонильной группы;
R3 представляет собой водородную группу и/или -N(R6)CONH(R7);
R6 и R7, которые могут быть одинаковыми или разными, каждый представляют собой (С1-С8) алкильную группу, которая может содержать третичную аминогруппу;
R4 представляет собой любую группу, выбранную из группы, состоящей из атома водорода, необязательно замещенной (С1-С6) алкильной группы и необязательно замещенной силильной группы;
R5 представляет собой атом водорода или необязательно замещенную (С1-С6) алкильную группу;
t представляет собой целое число от 45 до 450;
d и е каждый представляют собой целое число; d+е представляет собой целое число от 6 до 60; доля d относительно d+е составляет от 1% до 100%; доля е составляет от 0% до 99%; и
сегмент полиглутаминовой кислоты имеет структуру сегмента полиглутаминовой кислоты, в которой звенья глутаминовой кислоты, содержащие связанное с ними производное камптотецина, и звенья глутаминовой кислоты, содержащие связанную с ними R3 группу, каждое независимо расположены произвольным образом.
2. Фармацевтический препарат по п. 1, отличающийся тем, что указанный фармацевтический препарат представляет собой лиофилизированный препарат.
RU2018129760A 2016-03-01 2017-02-20 Фармацевтический препарат, содержащий полимерное производное на основе камптотецина RU2018129760A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-038943 2016-03-01
JP2016038943 2016-03-01
PCT/JP2017/006192 WO2017150256A1 (ja) 2016-03-01 2017-02-20 カンプトテシン類高分子誘導体を含有する医薬製剤

Publications (2)

Publication Number Publication Date
RU2018129760A true RU2018129760A (ru) 2020-04-01
RU2018129760A3 RU2018129760A3 (ru) 2020-04-01

Family

ID=59743985

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018129760A RU2018129760A (ru) 2016-03-01 2017-02-20 Фармацевтический препарат, содержащий полимерное производное на основе камптотецина

Country Status (10)

Country Link
US (1) US20190046653A1 (ru)
EP (1) EP3424513A4 (ru)
JP (1) JP6797182B2 (ru)
KR (1) KR20180114027A (ru)
CN (1) CN108697806A (ru)
AU (1) AU2017226131A1 (ru)
CA (1) CA3015459A1 (ru)
RU (1) RU2018129760A (ru)
TW (1) TW201731510A (ru)
WO (1) WO2017150256A1 (ru)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030023697A (ko) 2000-07-13 2003-03-19 다이이찌 세이야꾸 가부시기가이샤 Ｄｄｓ 화합물을 함유하는 의약 조성물
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
CN1309763C (zh) * 2002-10-31 2007-04-11 日本化药株式会社 喜树碱的高分子衍生物
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
EP2042195A1 (en) 2006-07-19 2009-04-01 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of combretastatin
WO2008041610A1 (fr) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
WO2008056596A1 (fr) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
CN101156854A (zh) * 2007-09-19 2008-04-09 哈尔滨峰源高科技开发有限公司 喜树碱类药物缓释微胶囊的制备方法
US20110293515A1 (en) * 2009-01-13 2011-12-01 The Uab Research Foundation Heterofunctional segment-poly (ethylene glycol) polymers as delivery vehicles
US9855261B2 (en) * 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
WO2015125640A1 (ja) * 2014-02-19 2015-08-27 日本化薬株式会社 カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途
WO2015125641A1 (ja) * 2014-02-19 2015-08-27 日本化薬株式会社 高分子化カンプトテシン誘導体及び高分子化ｈｓｐ９０阻害剤誘導体を含む医薬組成物
CA2969196C (en) * 2014-12-26 2021-04-13 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
EP3263107B1 (en) * 2015-02-23 2020-11-11 Nippon Kayaku Kabushiki Kaisha Block copolymer conjugate of physiologically active substance
WO2017038607A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
JP6797182B2 (ja) 2020-12-09
RU2018129760A3 (ru) 2020-04-01
WO2017150256A1 (ja) 2017-09-08
AU2017226131A1 (en) 2018-10-04
KR20180114027A (ko) 2018-10-17
CA3015459A1 (en) 2017-09-08
TW201731510A (zh) 2017-09-16
EP3424513A4 (en) 2019-10-23
EP3424513A1 (en) 2019-01-09
JPWO2017150256A1 (ja) 2018-12-27
US20190046653A1 (en) 2019-02-14
CN108697806A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
RU2016135922A (ru) Терапевтические соединения и композиции
EA202091508A1 (ru) 6-азаиндольные соединения
EA201491185A1 (ru) Полимеры альфа-аминоамидинов и их применение
RU2013132151A (ru) Некодирующий иммуномодулирующий днк конструкт
EA201791733A1 (ru) Производные 9h-пирролодипиридина
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
HRP20210562T1 (hr) Karbohidratni ligandi koji se vežu na igm antitijela koja djeluju protiv glikoproteina povezanog s mijelinom
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112014031052A2 (pt) composições processáveis no estado fundido tendo aditivos de processamento poliméricos contendo silicone
RU2017122809A (ru) Фармацевтический состав полимерного производного, содержащего камптотецин
RU2018109476A (ru) Полимерный коньюгат гексакоординированного комплекса платины
EA201792237A1 (ru) Фармацевтические составы
EA201690621A1 (ru) Полиэтиленгликольсодержащие композиции
PE20171510A1 (es) Copolimeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2
RU2018129760A (ru) Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
PE20170187A1 (es) Inhibidores de las vias de senalizacion de wnt
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
RU2017104223A (ru) Полиамины с определенной главной цепью
EP2644688A3 (en) Novel pyrimidine derivatives and their use in perfume compositions
RU2018102756A (ru) Фармацевтическая композиция, содержащая полимерное производное камптотецина
TR201820925T4 (tr) Azaindol türevi.
RU2015138732A (ru) Блок-сополиэфирсульфоны с дихлорэтиленовыми группами
TH180194A (th) อะโกนิสต์บางส่วนของอินซูลินรีเซพเตอร์